Surgery increases risk of conjunctival scars

Article

A greater number of mast cells are present in the conjunctiva of glaucoma patients who have undergone ocular surgery, possibly leading to increased scarring, according to study results published online ahead of print by Eye.

A greater number of mast cells are present in the conjunctiva of glaucoma patients who have undergone ocular surgery, possibly leading to increased scarring, according to study results published online ahead of print by Eye.

Lydia Chang of the Paediatric Glaucoma Service at Moorfields Eye Hospital, London, UK and colleagues identified the presence of tryptase, the intracellular mast cell enzyme, in the conjunctiva of glaucoma patients treated medically (n=6), with repeated surgery (n=8) and for uveitic glaucoma (n=7). They compared the tryptase levels with those found in the conjunctival biopsies of the control group (retinal detachment patients, n=8).

The median tryptase level of the control group was 0.064 cells/mm2; among the glaucoma groups, the median level ranged from 0.102 cells/mm2 to 0.113 cells/mm2. There was a statistically significant difference between the tryptase level of the surgery glaucoma group when compared with control, although this statistically significant difference did not exist between the control group and either of the other glaucoma groups.

Because the tryptase levels were higher in glaucoma patients who had previously undergone surgery, the researchers concluded that the activity of mast cells may contribute to post-trabeculectomy conjunctival scarring.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.